17 Results for "

PD-1 mAb

" in MedChemExpress (MCE) Product Catalog:
Products (17)

17 Results for "PD-1 mAb" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-P9971
CAS No.: 1798286-48-2
Synonyms: SHR-1210; INCSHR1210

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et,al .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P99100
CAS No.: 2556646-63-8
Synonyms: CTL-002

Research Areas:  

Cancer

Visugromab (CTL-002) is a GDF-15 neutralizing IgG4 mAb. Visugromab has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
Cat. No.: HY-P99499
CAS No.: 2050478-92-5
Synonyms: JNJ 63723283; JNJ 3283

Research Areas:  

Cancer

Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo .
loading...
    loading...
Cat. No.: HY-P99941
CAS No.: 2079108-44-2
Synonyms: INCMGA-00012; MGA-012

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Retifanlimab is an anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). Retifanlimab can be used for the research of gastroesophageal adenocarcinoma (GEA) .
loading...
    loading...
Cat. No.: HY-P99610
CAS No.: 2249882-54-8
Synonyms: BI-754091

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .
loading...
    loading...
Cat. No.: HY-P991345
Synonyms: AMP-514

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research .
loading...
    loading...
Cat. No.: HY-P991395

Target:  

Tim3

Research Areas:  

Cancer

TQB2618 is a human IgG4 monoclonal antibody (mAb) targeting TIM-3/HAVCR2/CD366. TQB2618 activates immune cell function and induces significant anti-tumor activity when used in combination with anti-PD-1 agents .
loading...
    loading...
Cat. No.: HY-P99100A
CAS No.: 2556646-63-8
Synonyms: CLT-002 (Powder)

Research Areas:  

Cancer

Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
loading...
    loading...
Cat. No.: HY-P991348

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. BAT-1306 can be used in Colorectal cancer and Solid tumours research .
loading...
    loading...
Cat. No.: HY-P991351

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

RTX-002 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. RTX-002 can be used to study autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis .
loading...
    loading...
Cat. No.: HY-158050
Target:  

c-Fms

Research Areas:  

Cancer

PXB17 can inhibit CSF1R (IC50 = 1.7 nM) by blocking the activation of PI3K/ AKT/mTORC1 signaling. PXB17 is orally effective. PXB17 significantly inhibits the growth of CRC, improves PD-1 mAb efficacy and reduces tumor recurrence in CRC .
loading...
    loading...
Cat. No.: HY-P991356
Synonyms: LAE-005

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

FAZ-053 is a human monoclonal antibody (mAb) targeting B7-H1/PD-L1/CD274. FAZ-053 inhibits the interaction of PD-L1 with PD-1 and B7-1 on monocytes, dendritic cells, and B cells. FAZ-053 enhances interleukin 2 production. FAZ-053 can be used in advanced alveolar soft tissue sarcoma (ASPS), chordoma, and triple-negative breast cancer research .
loading...
    loading...
Cat. No.: HY-P991347

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

AM0001 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. AM0001 can be used in cancer research .
loading...
    loading...
Cat. No.: HY-P991346

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

CC-90006 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. CC-90006 can be used in psoriasis research. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-P991353

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Sym-021 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. Sym-021 blocks the binding of PD-L1 and PD-L2 ligands, inducing the secretion of interferon IFN-γ and IL-2 and the proliferation of T cells. Sym-021 has anti-tumor activity in PDX mouse models .
loading...
    loading...
Cat. No.: HY-P991349

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

GNR-051 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. GNR-051 can be used in Solid tumours research .
loading...
    loading...
Cat. No.: HY-L031
813 compounds

Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.

MCE Small Molecule Immuno-Oncology Compound Library offers 813 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.

  • 1